



Contacts:

David Waldman or Justyna Gudaszewska
Crescendo Communications Europe Sp. z.o.o
Email: mmd@crescendo-ir.com
Tel: (+48 71) 79 11 551

Milestone Medical Inc. Submits Initial Results of Clinical Trial to Premier Pain Management Society for Publication

*CompuFlo technology objectively and accurately identifies the epidural space
when compared to radiological X-ray based fluoroscopy*

LIVINGSTON, NJ, October 22, 2015 -- Milestone Medical Inc. (WAR: MMD), today announced that it has submitted initial results of the Company's prospective, open labeled, clinical trial assessing the CompuFlo® technology in correctly identifying the epidural space during an epidural procedure to a prestigious American pain management society in advance of this organization's annual meeting in 2016.

Milestone Medical, Inc designed the study, in conjunction with its Scientific Advisory Board, and in agreement with the U.S. Food and Drug Administration (FDA), to assess the safety and effectiveness of the pressure sensing technology in identification of the epidural space.

Study results suggested that the non-invasive CompuFlo technology was able in a real time to objectively and accurately identify the epidural space when compared to radiological X-ray based fluoroscopy. Data suggested that the CompuFlo® technology has the potential to effectively avoid exposure of the patient to radiation.

Leonard Osser, Chief Executive Officer of Milestone Medical, added, "We are pleased to submit the initial results of our clinical trial and look forward to fully disclosing the data at this prestigious organization's annual meeting early next year."

About Milestone Medical Inc.

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete and the Company is currently pursuing regulatory approval for both instruments in the U.S. Milestone Medical received CE Mark approval to sell and market its intra-articular and epidural instruments across European Union. For more information please visit www.medicalmilestone.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2014. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.